Drugs / CS3006
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03736850 | Oct 2018 → May 2020 | — | CStone Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03516123 | Jun 2018 → Jun 2020 | cancer | CStone Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS3006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03736850 ↗ |
| Action | Inhibit | “MEK Inhibitor CS3006” NCT03516123 ↗ |
| Route | Oral | “Participants will receive CS3006 orally at specified dose on specified days” NCT03516123 ↗ |